Literature DB >> 15567640

Two measures of insulin sensitivity provided similar information in a U.S. population.

Dawn M Bravata1, Carolyn K Wells, John Concato, Walter N Kernan, Lawrence M Brass, Barbara I Gulanski.   

Abstract

BACKGROUND AND
OBJECTIVE: Two methods for measuring insulin sensitivity, fasting plasma insulin (FPI) and homeostasis model assessment (HOMA) have been proposed for use in large epidemiological research and clinical practice. This project describes the range of observed values of the HOMA and FPI in a large sample of the U.S. population.
METHODS: We used fasting plasma glucose and insulin values from the Third National Health and Nutrition Survey (NHANES III) to identify the FPI and HOMA values. For both FPI and HOMA, higher values indicate lower insulin sensitivity.
RESULTS: Among 6,511 participants without treated diabetes mellitus, FPI ranged from 1.8 to 175.8 microU/mL, with 25th percentile=6.7, median=9.3, 75th percentile=13.3, and mean+/-1 SD=11.2+/-7.5; HOMA ranged from 0.3 to 52.6 (mmol)(microU)/L(2), with 25th percentile=1.5, median=2.2, 75th percentile=3.3, and mean+/-SD=2.8+/-2.4.
CONCLUSION: These findings describe the spectrum of insulin sensitivity and may be useful in helping physicians develop a clinical understanding of the dynamic range of both FPI and HOMA measures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15567640     DOI: 10.1016/j.jclinepi.2004.05.001

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  13 in total

1.  Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease.

Authors:  Naoki Kumashiro; Derek M Erion; Dongyan Zhang; Mario Kahn; Sara A Beddow; Xin Chu; Christopher D Still; Glenn S Gerhard; Xianlin Han; James Dziura; Kitt Falk Petersen; Varman T Samuel; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 2.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

3.  Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia.

Authors:  Kevin C Oeffinger; Beverley Adams-Huet; Ronald G Victor; Timothy S Church; Peter G Snell; Andrea L Dunn; Debra A Eshelman-Kent; Robert Ross; Peter M Janiszewski; Alicia J Turoff; Sandra Brooks; Gloria Lena Vega
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

4.  Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up.

Authors:  F Ceccato; G Occhi; N M Albiger; S Rizzati; S Ferasin; G Trivellin; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

Review 5.  Insulin, cognition, and dementia.

Authors:  Brenna Cholerton; Laura D Baker; Suzanne Craft
Journal:  Eur J Pharmacol       Date:  2013-09-23       Impact factor: 4.432

6.  Insulin resistance causes human gallbladder dysmotility.

Authors:  Attila Nakeeb; Anthony G Comuzzie; Hayder Al-Azzawi; Gabriele E Sonnenberg; Ahmed H Kissebah; Henry A Pitt
Journal:  J Gastrointest Surg       Date:  2006 Jul-Aug       Impact factor: 3.452

Review 7.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged.

Authors:  Suzanne Craft
Journal:  Arch Neurol       Date:  2009-03

Review 8.  Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase.

Authors:  Medha Priyadarshini; Mohammad A Kamal; Nigel H Greig; Marcella Reale; Adel M Abuzenadah; Adeel G A Chaudhary; Ghazi A Damanhouri
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-06-01       Impact factor: 4.388

9.  Diets high in resistant starch increase plasma levels of trimethylamine-N-oxide, a gut microbiome metabolite associated with CVD risk.

Authors:  Nathalie Bergeron; Paul T Williams; Regina Lamendella; Nastaran Faghihnia; Alyssa Grube; Xinmin Li; Zeneng Wang; Rob Knight; Janet K Jansson; Stanley L Hazen; Ronald M Krauss
Journal:  Br J Nutr       Date:  2016-12-20       Impact factor: 3.718

10.  Exploring the Neuroprotective Potential of Rosiglitazone Embedded Nanocarrier System on Streptozotocin Induced Mice Model of Alzheimer's Disease.

Authors:  Sarathlal K C; Violina Kakoty; Sandhya Marathe; Deepak Chitkara; Rajeev Taliyan
Journal:  Neurotox Res       Date:  2020-07-18       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.